Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier:
NCT01155947
First received: July 1, 2010
Last updated: NA
Last verified: July 2010
History: No changes posted

July 1, 2010
July 1, 2010
May 2008
June 2008   (final data collection date for primary outcome measure)
Bioavailability based on Cmax and AUC parameters [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions
An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fasting Conditions.

The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.

Open label, balanced, randomized, two treatment, two-sequence, two periods, crossover, single dose, comparative oral bioavailability study in healthy, post menopausal women subjects under fasting conditions.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy
Drug: Anastrozole
Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Other Name: Arimidex® Tablets 1 mg
  • Active Comparator: Arimidex
    Arimidex® Tablets 1 mg
    Intervention: Drug: Anastrozole
  • Experimental: Anastrozole
    Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
    Intervention: Drug: Anastrozole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
July 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The subjects should be postmenopausal healthy women who have attained complete menopause naturally or surgically and have not had menstruation for at least one year and are not on hormone replacement therapy.
  2. The subjects should have Estradiol level ≤ 20 pg/ml & serum follicular stimulating hormone (FSH) level ≥ 50 mlU/ml during the screening.
  3. The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
  4. The subjects should have a BMI between 18.5 to 26.4 (30-39 years), 18.5 to 27.8 (40-49 years), 18.5 to 28.4 (50-59 years) & 18.5 to 27.5 (60-69 years) weight in kg/ height2 in meter.
  5. The subjects should be able to communicate effectively with study personnel.
  6. The subjects should be able to give written informed consent to participate in the study.

Exclusion Criteria:

  1. The subjects who have a history of allergic responses to Anastrozole or other related drugs.
  2. The subjects who are using female hormone replacement therapies, thyroid hormone replacement therapies, or antihypertensive therapies.
  3. The subjects who have significant diseases or clinically significant abnormal findings during screening, (medical history, physical examination, laboratory evaluations, ECG, X-ray & lower abdominal ultrasonography recordings).
  4. The subjects who have any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
  5. The subjects who have a history or presence of bronchial asthma.
  6. The subject who have used of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
  7. The subjects who have history of drug dependence, recent history of alcoholism or of moderate alcohol use.
  8. The subjects who are smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who cannot refrain from smoking during study period.
  9. The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
  10. The subjects who have donated (1 unit: 350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
  11. The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
  12. The subjects who have a positive test result for Human Immunodeficiency Virus (HIV) antibody and / or syphilis Rapid Plasma Reagin, Venereal Disease Research Laboratory (RPR/VDRL).
  13. The subject who received an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.
Female
37 Years to 67 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01155947
BA0859093
Yes
Dr. Ramesh Mullangi -Director, Dr.Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited
Not Provided
Principal Investigator: Mayur Soni, MBBS BA Research India Ltd.,
Dr. Reddy's Laboratories Limited
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP